Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
FOCL · Nasdaq · United States · Electromedical & Electrotherapeutic Apparatus
In shortEDAP TMS SA is loss-making, burns cash and holds more cash than debt, with revenue growing (+6.1% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -32.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -29.7% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -38.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -35.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.85× | 87/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.11× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -87.01× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -1.34 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -21.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 11.6% | 68/100 |
| Operating margin volatility | 16.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 13.3% | 91/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 42 | 44 | 55 | 60 | 64 |
| Cost of revenue | 23 | 26 | 31 | 36 | 38 |
| Gross profit | 18 | 18 | 24 | 24 | 27 |
| Research & development | 4.5 | 3.4 | 4.9 | 7 | 7.7 |
| Operating income | 0.3 | (1.6) | (4.3) | (20) | (21) |
| Interest expense | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 |
| Pre-tax income | (1.2) | 0.9 | (2.1) | (21) | (19) |
| Income tax | 0.5 | 0.2 | 0.8 | 0.6 | 0.3 |
| Net income | (1.7) | 0.7 | (2.9) | (21) | (19) |
| Diluted EPS | −€0.06 | €0.02 | −€0.09 | −€0.57 | −€0.51 |
| Diluted shares (millions) | 29 | 32 | 34 | 37 | 37 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−1.34 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Mar 25, 2026